AXA Framlington Health Income Units
Also available as accumulation units
At a glance
| Initial charge | 5.50% |
|---|---|
| Initial saving | 5.50% |
| Annual charge | 1.50% |
| Annual saving | 0.200% ² |
| Total Expense Ratio | 1.70% |
| Launch date | 24-04-1987 |
| Launch price | £0.50 |
| Sector | Specialist |
| Fund size | £238 million |
| Number of holdings | 92 |
| Fund type | Unit Trust |
| Type of units | Income |
Ways to Invest
Find out how to invest in this fundHL Research - Our view on this Fund
It would be fair to say that the healthcare sector has been poor in recent years, but given the events of the last year and a global economic slowdown, the sector could be coming back into favour. In uncertain times, investors turn their focus on what they believe to be more resilient businesses with predictable revenue streams like healthcare. This is proving positive for the shares of healthcare companies.
Full research
About the Fund Manager
Deane Donnigan
Located in: London
Deane attended University of Georgia and the Medical College of Georgia, spending 7 years working as a pharmacy intern and a registered pharmacist while working on her BS and PharmD degrees. After this, she worked for 2 years at the Medical College of Georgia Hospital and Clinics with paediatric and adult patients.
In 1990, Deane accepted a position with Emory University Hospital, Atlanta, Georgia, as a clinical specialist.
Deane joined AXA Framlington in October 1997.
1 of 2 
Income details
| Running yield | N/a |
|---|---|
| Income paid | Bi-annually |
| Type of payment | Dividend |
All yields are variable and not guaranteed. There is currently no yield information available for this fund.
Distribution dates
| Ex-dividend date | 30 June 2009 |
|---|---|
| Payment date ³ | 30 April 2009 |
1 of 2
Top 10 holdings
| Gilead Sciences | 3.56% |
|---|---|
| NuVasive | 3.13% |
| Alexion Pharmaceuticals | 2.50% |
| Thermo Fisher Scientific | 2.48% |
| BioMarin Pharmaceutical | 2.42% |
| Alcon | 2.34% |
| Celgene Corp. | 2.30% |
| HMS Holdings Corp. | 2.23% |
| Genzyme Corp. | 2.21% |
| Shire | 2.20% |
Top 10 sectors
| Pharmaceuticals & Biotechnology | 46.64% |
|---|---|
| Health Care Equipment & Services | 39.61% |
| Software & Computer Services | 7.00% |
| Food & Drug Retailers | 3.08% |
| Cash and Equiv. | 2.19% |
| Media | 1.48% |
Top 10 countries
| United States | 74.18% |
|---|---|
| United Kingdom | 7.62% |
| Switzerland | 6.16% |
| Cash and Equiv. | 2.19% |
| Germany | 2.02% |
| Japan | 1.73% |
| Denmark | 1.49% |
| Ireland | 1.28% |
| Hungary | 1.26% |
| Israel | 1.04% |
² Annual saving is not available in the SIPP.
³ If you elect to receive the income from a Vantage ISA, Fund or Share Account, we will collect any dividends for you and then pay them directly into your bank account within the first 10 working days of the following month.
Last valuation as at 07-01-2009. Data accurate as at 30/09/2008.
